Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
Joint Authors
Berrino, L.
De Angelis, A.
Gorini, Stefania
Malara, Natalia
Rosano, Giuseppe
Ferraro, Elisabetta
Source
Oxidative Medicine and Cellular Longevity
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-1, 1 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-06-26
Country of Publication
Egypt
No. of Pages
1
Main Subjects
Abstract EN
In the article titled “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib” [1], the author Giuseppe Rosano should have been affiliated to the first and fourth affiliations.
The corrected authors’ list is shown above.
American Psychological Association (APA)
Gorini, Stefania& De Angelis, A.& Berrino, L.& Malara, Natalia& Rosano, Giuseppe& Ferraro, Elisabetta. 2019. Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”. Oxidative Medicine and Cellular Longevity،Vol. 2019, no. 2019, pp.1-1.
https://search.emarefa.net/detail/BIM-1206488
Modern Language Association (MLA)
Gorini, Stefania…[et al.]. Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”. Oxidative Medicine and Cellular Longevity No. 2019 (2019), pp.1-1.
https://search.emarefa.net/detail/BIM-1206488
American Medical Association (AMA)
Gorini, Stefania& De Angelis, A.& Berrino, L.& Malara, Natalia& Rosano, Giuseppe& Ferraro, Elisabetta. Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”. Oxidative Medicine and Cellular Longevity. 2019. Vol. 2019, no. 2019, pp.1-1.
https://search.emarefa.net/detail/BIM-1206488
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1206488
